U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H43NO5
Molecular Weight 449.6233
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of URSODEOXYCHOLYLGLYCINE

SMILES

C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChIKey=GHCZAUBVMUEKKP-XROMFQGDSA-N
InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

HIDE SMILES / InChI
Molecular Formula C26H43NO5
Molecular Weight 449.6233
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
PubMed

PubMed

TitleDatePubMed
Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells.
2010-02
Bilirubin selectively inhibits cytochrome c oxidase activity and induces apoptosis in immature cortical neurons: assessment of the protective effects of glycoursodeoxycholic acid.
2010-01
Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
2009-06
Contribution of inflammatory processes to nerve cell toxicity by bilirubin and efficacy of potential therapeutic agents.
2009
Determination of bile acids in human serum by on-line restricted access material-ultra high-performance liquid chromatography-mass spectrometry.
2008-06-15
Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid.
2008-03
Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
2008-02
p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis.
2007-11-23
Glycoursodeoxycholic acid and interleukin-10 modulate the reactivity of rat cortical astrocytes to unconjugated bilirubin.
2007-09
Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate.
2007-02
Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8).
2006-05-12
Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.
2005-01
Ursodeoxycholic acid inhibits endothelin-1 production in human vascular endothelial cells.
2004-11-28
High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma.
2003-12-25
Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor.
2003-10
Interactions of combined bile acids on hepatocyte viability: cytoprotection or synergism.
2002-02-07
Whole-cell response characteristics of ciliated and microvillous olfactory receptor neurons to amino acids, pheromone candidates and urine in rainbow trout.
2001-11
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
1998-01
Positions of conjugation of bile acids with glucose and N-acetylglucosamine in vitro.
1994-09
pH-Solubility relations of chenodeoxycholic and ursodeoxycholic acids: physical-chemical basis for dissimilar solution and membrane phenomena.
1980-01
Patents

Patents

20010024658
2
20020012680
29
JP2002537317A
97
JP4790123B2
46
JPH09315979A
2
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:41:44 GMT 2025
Edited
by admin
on Mon Mar 31 22:41:44 GMT 2025
Record UNII
PF1G5J2X2A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLYCOURSODEOXYCHOLIC ACID
Preferred Name English
URSODEOXYCHOLYLGLYCINE
Common Name English
3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLANOYLGLYCINE
Systematic Name English
N-((3.ALPHA.,5.BETA.,7.BETA.)-3,7-DIHYDROXY-24-OXOCHOLAN-24-YL)GLYCINE
Systematic Name English
N-(3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLAN-24-OYL)GLYCINE
Systematic Name English
GLYCINE, N-((3.ALPHA.,5.BETA.,7.BETA.)-3,7-DIHYDROXY-24-OXOCHOLAN-24-YL)-
Systematic Name English
GLYCYLURSODEOXYCHOLIC ACID
Common Name English
URSODEOXYCHOLYLGLYCINE, (+)-
Common Name English
Code System Code Type Description
CHEBI
89929
Created by admin on Mon Mar 31 22:41:44 GMT 2025 , Edited by admin on Mon Mar 31 22:41:44 GMT 2025
PRIMARY
PUBCHEM
12310288
Created by admin on Mon Mar 31 22:41:44 GMT 2025 , Edited by admin on Mon Mar 31 22:41:44 GMT 2025
PRIMARY
FDA UNII
PF1G5J2X2A
Created by admin on Mon Mar 31 22:41:44 GMT 2025 , Edited by admin on Mon Mar 31 22:41:44 GMT 2025
PRIMARY
EPA CompTox
DTXSID20862344
Created by admin on Mon Mar 31 22:41:44 GMT 2025 , Edited by admin on Mon Mar 31 22:41:44 GMT 2025
PRIMARY
CAS
64480-66-6
Created by admin on Mon Mar 31 22:41:44 GMT 2025 , Edited by admin on Mon Mar 31 22:41:44 GMT 2025
PRIMARY
Related Record Type Details
Structure of URSODEOXYCHOLYLGLYCINE SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of GLYCOURSODEOXYCHOLIC ACID 3-SULFATE
METABOLITE -> PARENT
Unit: ng/mg creatinine; healthy volunteers (n=12)
IN-VIVO
URINE
Structure of SULFOLITHOCHOLYLGLYCINE
METABOLITE -> PARENT
IN-VIVO
FECAL
Structure of NUTRIACHOLIC ACID
METABOLITE -> PARENT
Unit: percent of total bile acids; Daily dose of UDCA: 1g (n=3); Duration: 2 weeks
IN-VIVO
FECAL
Structure of LITHOCHOLIC ACID
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
Structure of URSODEOXYCHOLIC ACID 3-O-.BETA.-D-GLUCOPYRANOSIDURONIDE
METABOLITE -> PARENT
IN-VITRO
Scientific Literature
Structure of URSODEOXYCHOLIC ACID 3-O-.BETA.-D-GLUCOPYRANOSIDURONIDE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
LCA-sulfate in serum of gallstone patients given UDCA (n=7; 750mg/day [250mg in the morning, 500mg in the evening] for 2 to 3 weeks); Control (n=5): 0.1 micromole/L
IN-VIVO
PLASMA
Structure of N-ACETYLGLUCOSAMINYL URSODEOXYCHOLYL GLYCINE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of URSODIOL
METABOLITE ACTIVE -> PARENT
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
Unit: micromole/24hr (baseline: 0.12 mcmol/24hr); Excretion of LCA-sulfate on day 10 of daily oral administration of 750mg UDCA to healthy volunteers
IN-VIVO
URINE
Structure of URSODEOXYCHOLIC ACID GLUCOSIDE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
Unit: micromole/g creatinine; LCA-sulfate in urine of gallstone patients given UDCA (n=6; 750mg/day [250mg in the morning, 500mg in the evening] for 2 to 3 weeks); Control (n=6): 0.4 micromole/g creatinine
IN-VIVO
URINE
Structure of SULFOLITHOCHOLIC ACID
METABOLITE -> PARENT
IN-VIVO
FECAL
Structure of URSODIOL
PARENT -> METABOLITE
Structure of LITHOCHOLIC ACID
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
Structure of N-ACETYLGLUCOSAMINYL URSODEOXYCHOLIC ACID
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of LITHOCHOLIC ACID
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
Structure of URSODEOXYCHOLIC ACID 3-SULFATE
METABOLITE -> PARENT
IN-VIVO
URINE
Structure of URSODEOXYCHOLIC ACID GLUCOSIDE
METABOLITE -> PARENT
IN-VITRO
Scientific Literature
Structure of NUTRIACHOLIC ACID
METABOLITE -> PARENT
Unit: percent of total bile acids; Daily dose of UDCA: 15mg/kg (n=6); Duration: 15 days; before treatment (7-KLCA in feces): 1 % of total bile acids
IN-VIVO
FECAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966